Tissue viability imaging (TiVi) in the assessment of divergent beam UV-B provocation

被引:0
作者
Jim O’Doherty
Joakim Henricson
Joey Enfield
Gert E. Nilsson
Martin J. Leahy
Chris D. Anderson
机构
[1] Royal Surrey County Hospital,Department of Medical Physics
[2] University of Limerick,Department of Physics
[3] Linköping University,Allergy Centre, University Hospital
[4] Wheelsbridge AB,Division of Dermatology, Department of Clinical and Experimental Medicine
[5] Linköping University,undefined
来源
Archives of Dermatological Research | 2011年 / 303卷
关键词
Photo-testing; Tissue viability imaging; UV-B; Microcirculation; Polarization spectroscopy; Minimal erythemal dose;
D O I
暂无
中图分类号
学科分类号
摘要
In routine clinical phototesting and in basic research, naked eye dermatological assessment is the “gold standard” for determining the patient’s minimal erythemal dose (MED). In UV-B testing with a divergent, radially attenuating beam of characterised dosimetry, laser Doppler perfusion imaging has been previously used to give quantitative description of reactivity to doses above the MED in addition to a “single-dose” objective determination of the MED itself. In the present paper, the recently developed tissue viability imaging (TiVi) technology is presented for the first time as a reliable, easily applicable, high-resolution alternative to LDPI in the divergent beam testing concept. Data obtained after provocation with a range of doses was analysed in order to determine the reaction diameter, which can be related to the MED using field dosimetry. The dose–response features of exposure above the MED and the relationship between naked eye readings and the diameter were determined from the image data. TiVi data were obtained faster than LDPI data and at a higher spatial resolution of 100 μm instead of 1 mm. A tool was developed to centre over the erythema area of the acquired image. Response data could be plotted continuously against dose. Thresholding of processed images compared to naked eye “gold standard” readings showed that the normal skin value +4 standard deviations produced a good fit between both methods. A linear fitting method for the dose–response data provided a further method of determination of the reaction diameter (MED). Erythemal “volume under the surface (VUS)” for the reaction provided a new concept for visualising information. TiVi offers advantages over LDPI in the acquisition and analysis of data collected during divergent beam testing. An increased amount of data compared to traditional phototesting is easily and more objectively obtained which increases applicability in the clinical and research environment.
引用
收藏
页码:79 / 87
页数:8
相关论文
共 123 条
  • [1] Ananthaswamy HN(1997)Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens Nat Med 3 510-514
  • [2] Loughlin S(2002)UV-B phototherapy clears psoriasis through local effects Arch Dermatol 138 1071-1076
  • [3] Cox P(2003)Phototesting with a divergent UV-B beam in the investigation of anti-inflammatory effects of topically applied substances Photodermatol Photo 19 195-202
  • [4] Evans RL(2008)Inter-observer variability in reading of phototest reactions with sharply or diffusely delineated borders Skin Res Technol 14 397-402
  • [5] Ullrich SE(2010)Reliability of self-assessed reading of skin tests—a possible approach in research and clinical practice? Dermatol Online J 16 4-75
  • [6] Kripke ML(2008)Prevention of skin cancer in primary healthcare: an evaluation of three different prevention effort levels and the applicability of a phototest Eur J Gen Pract 14 68-155
  • [7] Dawe RS(2008)Enhancement of visual scoring of skin irritant reactions using cross-polarized light and parallel-polarized light Contact Dermatitis 58 147-871
  • [8] Cameron H(1988)The validity and practicality of sun-reactive skin types I through VI Arch Dermatol 124 869-814
  • [9] Yule S(1998)Phototesting prior to narrowband (TL-01) ultraviolet B phototherapy Br J Dermatol 139 811-2158
  • [10] Man I(2006)Photoadaptation: a path toward rational phototherapy protocols J Invest Dermatol 126 2156-205